X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/unable-hit-licensing-deal-terms-basilea-will-return-cancer-drug-rights-merck
https://www.globenewswire.com/news-release/2022/04/13/2421542/0/en/Basilea-reports-preclinical-data-on-oncology-drug-candidates-BAL0891-derazantinib-and-lisavanbulin-at-AACR-Annual-Meeting.html
https://www.globenewswire.com/news-release/2022/01/24/2371306/0/en/Basilea-reports-updated-interim-results-for-iCCA-patients-with-FGFR2-mutations-and-amplifications-from-phase-2-study-FIDES-01-at-ASCO-GI-Cancers-Symposium.html
https://www.globenewswire.com/news-release/2021/10/11/2311499/0/en/Basilea-presents-preclinical-data-on-synergy-between-derazantinib-and-paclitaxel-in-gastric-tumor-models-at-ANE-Conference.html
https://www.globenewswire.com/news-release/2021/09/17/2298839/0/en/Basilea-presents-full-safety-and-efficacy-data-set-on-derazantinib-in-patients-with-FGFR2-fusion-positive-iCCA-at-ESMO-congress.html
https://www.globenewswire.com/news-release/2020/10/26/2113997/0/en/Basilea-presents-preclinical-data-on-anti-angiogenic-activity-of-derazantinib-at-ENA-2020.html#:~:text=Filings%20Media%20Partners-,Basilea%20presents%20preclinical%20data%20on%20anti%2Dangiogenic,of%20derazantinib%20at%20ENA%202020&text=Basilea%20Pharmaceutica%20Ltd.&text=The%20presented%20data%20from%20several,activity%20in%20FGFR%2Ddriven%20cancers.
https://www.basilea.com/news/news/basilea-reports-pooled-efficacy-data-for-derazantinib-in-icca-patients-with-fgfr2-gene-mutations-and-amplifications-presented-at-esmo-map-virtual-congress-2020?type=1546938654
https://www.globenewswire.com/news-release/2020/10/13/2107190/0/en/Basilea-reports-interim-results-from-phase-1-2-study-FIDES-02-exploring-derazantinib-in-patients-with-advanced-urothelial-cancer.html
https://www.globenewswire.com/news-release/2020/07/20/2064138/0/en/Basilea-announces-completion-of-patient-enrolment-into-first-cohort-of-phase-2-study-FIDES-01-with-derazantinib-in-bile-duct-cancer-iCCA.html
https://www.clinicaltrialsarena.com/news/basilea-derazantinib-trial-starts/
https://www.biospectrumasia.com/news/39/13351/nmpa-approves-sinovants-clinical-trial-application-for-derazantinib.html
https://www.businesswire.com/news/home/20190430006164/en/Sinovant-Sciences-Announces-Approval-Derazantinib%E2%80%99s-Clinical-Trial/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.fiercebiotech.com/biotech/basilea-slots-arqule-fgf-drug-into-its-cancer-portfolio
Market Place
Share 
